BioNTech Founders Exit to Launch New mRNA Venture Amid FDA Investigation

The co-founders of BioNTech are stepping down to create a new mRNA-focused company, signaling a strategic shift in immunotherapy development. This move comes amidst a U.S. Senate probe into the FDA's treatment decisions, highlighting regulatory challenges. Watch for how this new venture influences the biotech landscape and FDA interactions.